Menu
Recruiting NCT06371937

iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease

Observational Cardiovascular Diseases Arrythmia Cardiomyopathies Heart Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Cardiovascular Diseases, Arrythmia, Cardiomyopathies, Heart Failure. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Blood Biomarkers From Ethnically Diverse Cardiovascular Patients

Overview

The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.

Detailed description

Cardiovascular disease is the leading cause of morbidity and mortality. The development of cardiovascular disease includes both genetic and epigenetic factors. Understanding their molecular and cellular mechanism is necessary to identify novel drug targets and treat the disease. Present in vitro and in vivo models of the disease do not mimic human pathophysiology, and obtaining the primary cells from the patients for the studies relevant to the cardiovascular and pulmonary system is difficult. Induced pluripotent stem cells (iPSCs) are derived from a person's blood cells and facilitate the discovery of cardiovascular disease mechanisms. The Investigators propose recruiting cardiovascular patients from diverse ethnic backgrounds and creating a rich clinical database using REDCap. Blood samples will be obtained from participants and used to create iPSCs. The participant will have DNA sequencing, and serum will be analyzed for protein biomarkers. The multi-omics data and reprogrammed iPSCs will be stored in the Cardiology and Critical Care (C3RP) laboratory at the Robarts Research Institute at Western University. The reprogrammed iPSCs can generate a limitless supply of cardiovascular tissue. Moreover, the iPSC-derived data will be correlated with clinical information, genetic sequencing, and protein biomarkers from serum analysis. The Investigators expect to create an iPSC biobank coupled with a rich clinical dataset, including genetic sequencing analysis and protein biomarkers that will enable the discovery of novel biomarkers and drug targets for cardiovascular disease.

Primary outcome measures

  • REDCap Database [Time frame: 10 years]
  • Induced pluripotent stem cell (iPSC) Biobank [Time frame: 10 years]
  • Differentiation into Cardiovascular lineages [Time frame: 10 years]
  • Molecular profiling of participants [Time frame: 10 years]
  • Bioinformatics analysis [Time frame: 10 years]

Eligibility criteria

Inclusion criteria

  • Adult (18 to 80 years of age)
  • Cardiovascular Disease (CVD)
  • Cerebrovascular Disease (CBD)
  • Peripheral Vascular Disease (PVD)
  • Inherited Arrhythmias
  • Cardiomyopathies
  • Congenital Heart Disease (CHD)
  • Aortopathy
  • Hypertension
  • Cardiometabolic Disease (CMD)

Exclusion criteria

  • Younger than 18 years of age.
  • Patients not able to provide consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Other

Study locations

Canada · 1 center
  • London Regional Health Science Centre — London

Identifiers

NCT: NCT06371937 · 120687

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗